Skip to content

Study · Randomized controlled trial · n = 42 · 2007

9 results

[Effects of thymosin-alpha1 on cell immunity function in patients with septic shock].

Chen J

Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue1 Mar 2007Cited by 8 (Europe PMC)

PMID17376268 (opens in a new tab)PepBankPUB-17376268
Publisher pageAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with septic shock, CD3+ cell levels increased in the thymosin alpha‑1 group.

    In plain wordsIn patients with septic shock, CD3+ immune cell levels rose in the thymosin alpha‑1 group.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCD3+ T cell level
    Study

    n = 42

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    1.6 mg twice daily · subcutaneous · 1 weekAs given in this study (human).

    Source sentences

    Summary
    In the thymosin group, the levels of CD3+, CD4+, NK cells and the ratio of CD4+/CD8+ were increased obviously (all P<0.01).
    2 context sentences
    Summary · context
    Forty-two patients with septic shock in the department of intensive care unit (ICU) and acute physiology and chronic health evaluation II (APACHE II) scores between 15 and 25.
    Summary · context
    Patients in thymosin group were treated with thymosin-alpha1 1.6 mg by subcutaneous injection twice daily for 1 week in addition to the administration of broad-spectrum antibiotics to all patients.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with septic shock, CD4+ cell levels increased in the thymosin alpha‑1 group.

    In plain wordsIn patients with septic shock, CD4+ immune cell levels rose in the thymosin alpha‑1 group.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCD4+ T cell level
    Study

    n = 42

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    1.6 mg twice daily · subcutaneous · 1 weekAs given in this study (human).

    Source sentences

    Summary
    In the thymosin group, the levels of CD3+, CD4+, NK cells and the ratio of CD4+/CD8+ were increased obviously (all P<0.01).
    2 context sentences
    Summary · context
    Forty-two patients with septic shock in the department of intensive care unit (ICU) and acute physiology and chronic health evaluation II (APACHE II) scores between 15 and 25.
    Summary · context
    Patients in thymosin group were treated with thymosin-alpha1 1.6 mg by subcutaneous injection twice daily for 1 week in addition to the administration of broad-spectrum antibiotics to all patients.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with septic shock, natural killer cell levels increased in the thymosin alpha‑1 group.

    In plain wordsIn patients with septic shock, natural killer cell levels rose in the thymosin alpha‑1 group.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseNK cell level
    Study

    n = 42

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    1.6 mg twice daily · subcutaneous · 1 weekAs given in this study (human).

    Source sentences

    Summary
    In the thymosin group, the levels of CD3+, CD4+, NK cells and the ratio of CD4+/CD8+ were increased obviously (all P<0.01).
    2 context sentences
    Summary · context
    Forty-two patients with septic shock in the department of intensive care unit (ICU) and acute physiology and chronic health evaluation II (APACHE II) scores between 15 and 25.
    Summary · context
    Patients in thymosin group were treated with thymosin-alpha1 1.6 mg by subcutaneous injection twice daily for 1 week in addition to the administration of broad-spectrum antibiotics to all patients.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In patients with septic shock, the CD4+/CD8+ ratio increased in the thymosin alpha‑1 group.

    In plain wordsIn patients with septic shock, the CD4+/CD8+ immune cell ratio rose in the thymosin alpha‑1 group.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCD4+/CD8+ ratio
    Study

    n = 42

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    1.6 mg twice daily · subcutaneous · 1 weekAs given in this study (human).

    Source sentences

    Summary
    In the thymosin group, the levels of CD3+, CD4+, NK cells and the ratio of CD4+/CD8+ were increased obviously (all P<0.01).
    2 context sentences
    Summary · context
    Forty-two patients with septic shock in the department of intensive care unit (ICU) and acute physiology and chronic health evaluation II (APACHE II) scores between 15 and 25.
    Summary · context
    Patients in thymosin group were treated with thymosin-alpha1 1.6 mg by subcutaneous injection twice daily for 1 week in addition to the administration of broad-spectrum antibiotics to all patients.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In patients with septic shock, thymosin alpha‑1 shortened the mean afebrile period compared with control.

    In plain wordsIn patients with septic shock, the fever-free period was shorter with thymosin alpha‑1 than in the control group.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseAfebrile period
    Study

    n = 42

    Comparator
    Control group
    Outcome group
    Intensive care and hospital outcomes · Whole body
    Studied dose
    1.6 mg twice daily · subcutaneous · 1 weekAs given in this study (human).

    Source sentences

    Summary
    The mean afebrile period, stay days in ICU, duration of mechanical ventilation and hospital expenses as well as 28-day mortality were decreased obviously compared with those of control group (all P<0.01).
    2 context sentences
    Summary · context
    Forty-two patients with septic shock in the department of intensive care unit (ICU) and acute physiology and chronic health evaluation II (APACHE II) scores between 15 and 25.
    Summary · context
    Patients in thymosin group were treated with thymosin-alpha1 1.6 mg by subcutaneous injection twice daily for 1 week in addition to the administration of broad-spectrum antibiotics to all patients.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In patients with septic shock, thymosin alpha‑1 shortened ICU stay compared with control.

    In plain wordsIn patients with septic shock, ICU stays were shorter with thymosin alpha‑1 than in the control group.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseICU stay
    Study

    n = 42

    Comparator
    Control group
    Outcome group
    Intensive care and hospital outcomes · Whole body
    Studied dose
    1.6 mg twice daily · subcutaneous · 1 weekAs given in this study (human).

    Source sentences

    Summary
    The mean afebrile period, stay days in ICU, duration of mechanical ventilation and hospital expenses as well as 28-day mortality were decreased obviously compared with those of control group (all P<0.01).
    2 context sentences
    Summary · context
    Forty-two patients with septic shock in the department of intensive care unit (ICU) and acute physiology and chronic health evaluation II (APACHE II) scores between 15 and 25.
    Summary · context
    Patients in thymosin group were treated with thymosin-alpha1 1.6 mg by subcutaneous injection twice daily for 1 week in addition to the administration of broad-spectrum antibiotics to all patients.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In patients with septic shock, thymosin alpha‑1 shortened mechanical ventilation compared with control.

    In plain wordsIn patients with septic shock, time on a ventilator was shorter with thymosin alpha‑1 than in the control group.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseDuration of mechanical ventilation
    Study

    n = 42

    Comparator
    Control group
    Outcome group
    Intensive care and hospital outcomes · Whole body
    Studied dose
    1.6 mg twice daily · subcutaneous · 1 weekAs given in this study (human).

    Source sentences

    Summary
    The mean afebrile period, stay days in ICU, duration of mechanical ventilation and hospital expenses as well as 28-day mortality were decreased obviously compared with those of control group (all P<0.01).
    2 context sentences
    Summary · context
    Forty-two patients with septic shock in the department of intensive care unit (ICU) and acute physiology and chronic health evaluation II (APACHE II) scores between 15 and 25.
    Summary · context
    Patients in thymosin group were treated with thymosin-alpha1 1.6 mg by subcutaneous injection twice daily for 1 week in addition to the administration of broad-spectrum antibiotics to all patients.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In patients with septic shock, thymosin alpha‑1 lowered hospital expenses compared with control.

    In plain wordsIn patients with septic shock, hospital costs were lower with thymosin alpha‑1 than in the control group.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseHospital expenses
    Study

    n = 42

    Comparator
    Control group
    Outcome group
    Intensive care and hospital outcomes · Whole body
    Studied dose
    1.6 mg twice daily · subcutaneous · 1 weekAs given in this study (human).

    Source sentences

    Summary
    The mean afebrile period, stay days in ICU, duration of mechanical ventilation and hospital expenses as well as 28-day mortality were decreased obviously compared with those of control group (all P<0.01).
    2 context sentences
    Summary · context
    Forty-two patients with septic shock in the department of intensive care unit (ICU) and acute physiology and chronic health evaluation II (APACHE II) scores between 15 and 25.
    Summary · context
    Patients in thymosin group were treated with thymosin-alpha1 1.6 mg by subcutaneous injection twice daily for 1 week in addition to the administration of broad-spectrum antibiotics to all patients.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In patients with septic shock, thymosin alpha‑1 lowered 28-day mortality compared with control.

    In plain wordsIn patients with septic shock, fewer died within 28 days with thymosin alpha‑1 than in the control group.

    Peptide
    Thymosin alpha-1
    Outcome
    Decrease28-day mortality
    Study

    n = 42

    Comparator
    Control group
    Outcome group
    Mortality · Infection
    Studied dose
    1.6 mg twice daily · subcutaneous · 1 weekAs given in this study (human).

    Source sentences

    Summary
    The mean afebrile period, stay days in ICU, duration of mechanical ventilation and hospital expenses as well as 28-day mortality were decreased obviously compared with those of control group (all P<0.01).
    2 context sentences
    Summary · context
    Forty-two patients with septic shock in the department of intensive care unit (ICU) and acute physiology and chronic health evaluation II (APACHE II) scores between 15 and 25.
    Summary · context
    Patients in thymosin group were treated with thymosin-alpha1 1.6 mg by subcutaneous injection twice daily for 1 week in addition to the administration of broad-spectrum antibiotics to all patients.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.